Northstar Asset Management LLC maintained its position in Merck & Company, Inc. (NYSE:MRK) during the second quarter, according to its most recent filing with the SEC. The firm owned 18,194 shares of the company’s stock at the end of the second quarter. Northstar Asset Management LLC’s holdings in Merck & were worth $1,166,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cascade Investment Advisors Inc. raised its position in Merck & by 15.5% in the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after buying an additional 232 shares during the last quarter. Vigilant Capital Management LLC raised its stake in shares of Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares in the last quarter. Harbour Capital Advisors LLC bought a new stake in shares of Merck & during the first quarter worth $127,000. Gradient Investments LLC raised its stake in shares of Merck & by 41.3% in the first quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock worth $147,000 after buying an additional 674 shares in the last quarter. Finally, Pinnacle Bank bought a new stake in shares of Merck & during the first quarter worth $152,000. 73.00% of the stock is owned by institutional investors and hedge funds.

Shares of Merck & Company, Inc. (MRK) traded down 0.28% during mid-day trading on Tuesday, reaching $63.14. The company had a trading volume of 3,242,112 shares. The stock has a 50 day moving average price of $62.73 and a 200 day moving average price of $63.80. The firm has a market capitalization of $172.21 billion, a PE ratio of 34.19 and a beta of 0.80. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80.

Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. Merck &’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the business posted $0.93 EPS. On average, equities analysts forecast that Merck & Company, Inc. will post $3.87 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.97%. Merck &’s dividend payout ratio (DPR) is presently 76.11%.

ILLEGAL ACTIVITY WARNING: “Merck & Company, Inc. (MRK) Stake Maintained by Northstar Asset Management LLC” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/29/merck-company-inc-mrk-stake-maintained-by-northstar-asset-management-llc.html.

A number of analysts recently commented on the stock. J P Morgan Chase & Co boosted their target price on shares of Merck & from $74.00 to $76.00 and gave the stock an “overweight” rating in a report on Thursday, May 11th. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Credit Suisse Group reiterated a “buy” rating on shares of Merck & in a research note on Tuesday, June 13th. Vetr upgraded shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price objective on the stock in a research note on Monday, May 15th. Finally, Cowen and Company reissued a “market perform” rating and issued a $70.00 target price (up from $68.00) on shares of Merck & in a research report on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $69.63.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.